LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract
Summary
Leidos Holdings ($LDOS) received a $338M delivery order from the NIH National Cancer Institute for operational support in FY26-FY27. This award represents ~2.2% of Leidos' annual revenue and reinforces its role in federal health research services.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Leidos wins $338M NIH contract for NCI operations, adding to backlog.
- 2.Contract is ~2.2% of Leidos' annual revenue, a meaningful but not transformative boost.
- 3.Reinforces Leidos' position in federal health services, a stable growth area.
Market Implications
For $LDOS, this contract adds to a growing backlog in health services, supporting revenue visibility. The stock may see a slight positive drift as the market prices in the award, but given Leidos' size, the impact is modest. No other publicly traded companies are directly affected.
Full Analysis
- Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings ($LDOS), was awarded a $338M delivery order by the National Institutes of Health's National Cancer Institute. The contract covers operational task orders for FY26-FY27, supporting NCI's mission. 2) Leidos Holdings, a $15.3B revenue company, will see this $338M contract contribute to its Health segment, which provides scientific, technical, and operational services to federal health agencies. This is a meaningful but not transformative addition, representing ~2.2% of annual revenue. 3) While no specific bill directly authorizes this contract, the broader NIH budget is supported by annual appropriations bills. Related bills like HR9672 (Vaccine Injury Compensation) and HR9675 (opioid grants) signal continued healthcare spending, but this contract is a routine operational award. 4) Key subcontractors may include small-cap IT and lab services firms, but specific names are not disclosed. Leidos often partners with specialized research organizations. 5) Historically, Leidos has maintained a strong relationship with NIH, and such task orders provide predictable revenue streams. The stock tends to react modestly to contract wins of this size, with sustained performance tied to overall federal health spending.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, for operational support at the National Cancer Institute.
Who must act
Department of Health and Human Services / National Institutes of Health awarding to Leidos Biomedical Research Inc.
What happens
$338M added to Leidos' backlog, representing approximately 2.2% of FY2025 revenue ($15.3B).
Stock impact
Leidos' Health segment, which includes biomedical research services, will see a meaningful boost. This contract reinforces Leidos' position as a key NIH contractor, supporting stable revenue growth in a high-margin services area.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Department of Homeland Security Appropriations Act, 2027
LEIDOS BIOMEDICAL RESEARCH INC: $342M Department of Health and Human Services Contract
Slash the Pentagon Act
VICTIM Act of 2026
To prohibit Federal agencies from purchasing or accessing automated surveillance systems that identify, track, or record individuals, and for other purposes.
FIT Procurement Act
To amend the Homeland Security Act of 2002 to direct the Secretary of Homeland Security, acting through the Commissioner of U.S. Customs and Border Protection, to implement large-scale, non-intrusive inspection technology at land ports of entry identified as high risk, and for other purposes.
U.S. Customs and Border Protection Officer Retirement Technical Corrections Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Contract Details
Recipient
LEIDOS BIOMEDICAL RESEARCH INC
Award Amount
$337,911,652
Awarding Agency
Department of Health and Human Services
Sub-Agency
National Institutes of Health
Contract Type
DELIVERY ORDER
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →